Cantor Fitzgerald Starts Coverage On Spring Bank Pharma (SBPH) with $29 Target, Insmed (INSM) Shorts Increased By 2.22%

July 20, 2017 - By Maria Brooks

Insmed Incorporated (NASDAQ:INSM) had an increase of 2.22% in short interest. INSM’s SI was 3.82 million shares in July as released by FINRA. Its up 2.22% from 3.74 million shares previously. With 277,200 avg volume, 14 days are for Insmed Incorporated (NASDAQ:INSM)’s short sellers to cover INSM’s short positions. The SI to Insmed Incorporated’s float is 7.56%. It closed at $16.78 lastly. It is down 57.88% since July 20, 2016 and is uptrending. It has outperformed by 41.18% the S&P500.

It closed at $14.2 lastly. It is down 10.60% since July 20, 2016 and is uptrending. It has underperformed by 6.10% the S&P500.

Among 7 analysts covering Insmed (NASDAQ:INSM), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Insmed had 9 analyst reports since August 10, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, July 10 by Robert W. Baird. The rating was downgraded by UBS to “Neutral” on Monday, November 9. The firm earned “Buy” rating on Tuesday, March 15 by Stifel Nicolaus. The rating was upgraded by Zacks to “Hold” on Thursday, August 20. As per Monday, August 10, the company rating was downgraded by Zacks. The firm has “Buy” rating given on Friday, September 4 by Zacks. As per Wednesday, March 16, the company rating was maintained by Citigroup. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, October 6.

Investors sentiment increased to 1.52 in Q4 2016. Its up 0.37, from 1.15 in 2016Q3. It is positive, as 12 investors sold Insmed Incorporated shares while 21 reduced holdings. 16 funds opened positions while 34 raised stakes. 57.00 million shares or 0.75% more from 56.58 million shares in 2016Q3 were reported. Geode Capital Mngmt Ltd Liability stated it has 0% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Proshare Advsr Ltd Limited Liability Company reported 0.01% in Insmed Incorporated (NASDAQ:INSM). California State Teachers Retirement System holds 0% of its portfolio in Insmed Incorporated (NASDAQ:INSM) for 127,548 shares. 70,949 were accumulated by Rhumbline Advisers. Susquehanna Grp Ltd Liability Partnership holds 115,572 shares. The Georgia-based Voya Inv Limited Liability has invested 0% in Insmed Incorporated (NASDAQ:INSM). 10,667 were accumulated by Hsbc Public Ltd Com. Tudor Corp Et Al reported 22,887 shares. Jpmorgan Chase And Communications invested 0% of its portfolio in Insmed Incorporated (NASDAQ:INSM). 73,262 are held by Qs Ltd Com. 63,143 are held by Pictet Asset. State Street invested in 0% or 1.43 million shares. Goldman Sachs Group Inc holds 0% or 279,365 shares in its portfolio. Baker Bros Advisors L P holds 0.05% in Insmed Incorporated (NASDAQ:INSM) or 400,000 shares. Blackrock Invest Mngmt Limited Company invested 0% in Insmed Incorporated (NASDAQ:INSM).

Insmed Incorporated is a biopharmaceutical company. The company has market cap of $1.03 billion. The Firm operates through development and commercialization of therapies for patients with rare diseases segment. It currently has negative earnings. The Company’s lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation , which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Since March 1, 2017, it had 1 buying transaction, and 1 insider sale for $178,818 activity. 10,000 shares were bought by Pellizzari Christine A, worth $151,382 on Tuesday, May 30. 20,000 Insmed Incorporated (NASDAQ:INSM) shares with value of $330,200 were sold by Drechsler Andrew T.

Analysts await Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) to report earnings on August, 7. They expect $-0.48 earnings per share, up 22.58% or $0.14 from last year’s $-0.62 per share. After $-0.47 actual earnings per share reported by Spring Bank Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 2.13% negative EPS growth.